Background: Many hypertensive patients require combination therapy to achieve target blood pressure (BP). ␤-Blockers and dihydropyridine calcium channel blockers are effective as monotherapy in hypertensive patients and have complementary mechanisms for lowering BP.
D
espite the known importance of treating high blood pressure (BP) to prevent cardiovascular complications such as stroke and myocardial infarction, most hypertensive patients do not achieve target, optimal risk-lowering BP. As recently as the year 2000, only 34% of treated patients with systolic BP (SBP) Ն140 mm Hg or diastolic BP (DBP) Ն90 mm Hg attained target BP. 1 The gap between public awareness and control to target BP indicates that public health goals for hypertension are not being achieved despite many available treatment options. In 2003, the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) recommended aggressive treatment of hypertensive patients and stressed the importance of combination therapy, particularly for those at high risk. 1 The requirement for combination therapy was very apparent in the large Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) trial. 2 In ALLHAT, Ͼ40% of patients required Ն2 antihypertensive agents after 4 years, regardless of the assigned initial treatment, 2 thereby supporting the concept that combination therapy can take advantage of the complementary mechanisms of action of different drug classes, and that this facilitates attainment of goal BP levels. 3 Among the drug classes recommended for treating patients with hypertension, the JNC describes a role for ␤-blockers and calcium channel blockers. Both classes lower BP and large clinical trials indicate that they reduce the risk for the cardiovascular consequences of hypertension. 4 -9 Extended-release (ER) metoprolol succinate is a ␤ 1 -selective (cardioselective) adrenoceptor-blocking agent approved for treatment of hypertension, stable angina pectoris, and stable symptomatic heart failure (New York Heart Association class II or III). Felodipine ER is a dihydropyridine calcium channel blocker that is highly selective for vascular smooth muscle and also is approved for the treatment of patients with hypertension. Taken together, these agents have demonstrated complementary antihypertensive effects in studies of several fixed-dose levels. 7,10 -17 Although calcium channel blocker/␤-blocker combination products, including ER felodipine/ER metoprolol succinate, are available in many European countries, none are currently available in the United States.
To characterize comprehensively this specific calcium channel blocker/␤-blocker combination over a wide dose range, the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT) evaluated the antihypertensive efficacy and safety of once-daily ER metoprolol succinate monotherapy (25, 100, and 400 mg), ER felodipine monotherapy (2.5, 10, and 20 mg), and their nine combinations in adult patients with essential hypertension.
Patients and Methods
Written informed consent was obtained from all patients, and the study protocol was approved by the responsible institutional review boards.
Patients
Investigators enrolled men and women ages 18 to 80 years with uncomplicated essential hypertension whose sitting diastolic BP (SiDBP) following a 4-or 5-week placebo run-in period was between 95 and 114 mm Hg. The protocol excluded patients with intolerance or contraindications to the agents (pregnancy, bronchospastic pulmonary disease, high level heart block, marked bradycardia); unstable concurrent medical conditions (recent myocardial infarction, stroke, coronary artery intervention, or severe liver disease); sitting systolic BP (SiSBP) Ͼ200 mm Hg; or use of concomitant therapies known to affect BP.
Study Design
The M-FACT trial was a US multicenter, randomized, double-blind, placebo-controlled, parallel-group, unbalanced factorial study. After a 4-or 5-week single-blind placebo run-in, eligible patients entered a 9-week, doubleblind treatment period, followed by a 2-week, doubleblind, down-titration period (Fig. 1) .
After the placebo run-in, patients meeting BP criteria were randomized to one of the 16 treatment groups. Patients assigned to ER felodipine 20 mg and/or ER metoprolol succinate 400 mg received half doses for 1 week before escalation to the full dose. Post-randomization clinic visits were at weeks 1, 3, 5, 9, and 11.
Randomization and Blinding
A computer-generated randomization schedule allocated patients to treatment groups in blocks within each study center. The ER felodipine and ER metoprolol succinate (and matching placebos) were administered as separate tablets once daily before 10 AM. To maintain blinding, patients received 6 active or placebo tablets or both each morning, packaged according to a double-dummy dosing scheme.
Efficacy Assessments
Blood pressure was measured by mercury sphygmomanometry. The mean of three readings to the nearest 2 mm Hg comprised each BP determination. Diastolic BP was recorded at Korotkoff phase V. At the investigators' discretion, patients with SiDBP consistently Ͼ110 mm Hg could be discontinued for "lack of therapeutic effect." The primary efficacy measure was change from baseline to week 9 in trough (24 Ϯ 2 h post-dosing) SiDBP. Secondary variables included SiSBP, standing SBP, and DBP.
Safety Assessments
Safety measures included adverse events (AE) (spontaneously reported or elicited), clinical chemistry, hematology and urinalysis tests, physical examinations, and 12-lead electrocardiographic findings.
Statistical Methods
The sample size estimate of 1152 patients considered the assumptions: SiDBP differences of 3.5 mm Hg, standard deviation of the difference of 8 mm Hg, two-sided significance level of 0.050, power of 80%, and a 15% dropout rate. The study used an unbalanced design where targeted dose combinations received larger sample sizes to ensure sufficient power but included a sufficient number of dose levels to allow for a full dose-response characterization ( Fig. 1) .
Efficacy analyses used an intent-to-treat (ITT) population (all randomized patients receiving one or more dose of study drug and with one or more post-baseline efficacy measurements) and analysis of covariance (ANCOVA) statistical models for change from baseline to week 9 with factors for treatments and center, and with baseline BP as the covariate. Treatment-by-treatment interaction also was included. P values and 95% confidence intervals were calculated for pairwise differences. Missing week-9 values were imputed by carrying forward the last valid observation. Additivity was described as the difference of the effect of a combination and the sum of the effects of the individual agents. A MIN test was included to identify combinations for which the observed response was significantly better than both monotherapies, and the resulting P values were adjusted for multiplicity. 18, 19 The safety population included all randomized patients who received one or more doses of study drug; findings were descriptively summarized.
Statistical analyses were performed with the GAUSS from Aptech Systems, Inc. (Bellevue, WA), and the Riemann Library (GAUSS kernel revision 6.0.11; Riemann Library, version 2.2.1).
Results

Patient Disposition and Baseline Characteristics
A total of 1649 subjects were enrolled, 1092 of whom met randomization eligibility criteria. Of those randomized, 191 patients discontinued, including one who discontinued before receiving treatment and four with no post-baseline BP measurements. The efficacy (ITT) population included 1087 patient and the safety population 1091 patients.
A little more than half of the patients were men; 15% were Ն65 years of age (mean age 54 years) and most had a long history of hypertension (mean 9 years) ( Table 1) . The study included African Americans (13%) and diabetic patients (11%). At randomization, mean SiSBP/SiDBP was 152.6/99.9. Despite the many treatments, groups were well balanced for baseline characteristics. Study drug compliance as estimated from the difference in study drug dispensed and returned was Ͼ93% for 95% of patients.
Treatment Efficacy
SiDBP The SiDBP declined from baseline to week 9 in all treatment groups, largely in a dose-dependent and monotonic fashion. Monotherapy with ER metoprolol succinate resulted in an adjusted (by ANCOVA model) mean decrease in SiDBP of 7.7 mm Hg (25 mg), 9.4 mm Hg (100 mg), and 11.1 mm Hg (400 mg). Comparable dosedependent declines occurred with ER felodipine monotherapy, with mean decreases ranging from 7.7 to 11.8 mm Hg. Combination therapy resulted in generally larger decreases, ranging from 11.0 to 16.5 mm Hg, reflecting the additive contributions of the components (Table 2 ). Figure  2 illustrates these mean changes in SiDBP across all treatment groups after subtraction of the 4.0 -mm Hg placebo effect. The treatment interaction term in the model was not significant (P ϭ .435) implying additivity of the individual agent effects over the dose range.
In pairwise comparisons, each of the nine felodipine- BMI ϭ body mass index; SiDBP ϭ sitting diastolic blood pressure; SiSBP ϭ sitting systolic blood pressure.
metoprolol combinations was more effective in lowering SiDBP than the individual components (P Ͻ .05) for all but the felodipine 20 mg/metoprolol 25 mg combination versus felodipine 20 mg (data not shown). Eleven treatment contrasts of interest were specified, nine of which described the efficacy of the lowest doses of each agent, as well as low-dose combinations versus highdose monotherapy (Table 3) . These treatment contrasts indicated that both low-dose felodipine (2.5 mg) and metoprolol (25 mg) were more effective than placebo and that the felodipine 2.5 mg/metoprolol 25 mg combination was more effective than its individual components and placebo. Furthermore, this low-dose combination proved approximately as effective as the highest doses of the individual monotherapies (felodipine 20 mg and metoprolol 400 mg).
SiSBP The findings for SiSBP were similar to those for SiDBP, as values declined with all treatments. The decline with the monotherapies tended to be dose-related and monotonic with the exception of the 100-mg ER metoprolol dose. The combinations were, again, more effective than their components (Table 4 , Fig. 3 ).
Combinations
The magnitude of the additivity of the agents is described in Table 5 . The table displays the difference of the mean changes in SiDBP for combinations versus the sum of the two components. A negative result indicates that the combination performed better than would be expected based on the results for each drug individually. For all combinations except high-dose felodipine (20 mg), the observed measurements were within 1 mm Hg of the fully additive expectations.
Acknowledging a lesser clinical interest in the felodipine 20-mg dose because of its limited tolerability, additional analyses (MIN test) compared all other combinations to their individual components both with and without adjustment for multiplicity. Each combination proved significantly superior to each of its components even with the multiplicity adjustment (Table 6 ).
Other Outcomes and Subgroups
The findings for standing BP closely paralleled those for sitting BP, and no notable acute postural decline in mean BP was seen (data not shown). As expected for a ␤-blocker, heart rate decreased in a dose-related manner with ER metoprolol succinate (range, Ϫ1.3 to Ϫ10.1 beats/min). Little change occurred with ER felodipine, and ANCOVA ϭ analysis of covariance; ER ϭ extended-release; SiDBP ϭ sitting diastolic blood pressure. * Adjusted by analysis of covariance. combination treatment largely reflected the effect of ER metoprolol succinate (range, Ϫ2.0 to Ϫ12.8 beats/min); that is, ER felodipine did not add to or offset the reduction in heart rate that was associated with ER metoprolol succinate. Subgroup analyses of sitting BP based on age (Ͻ65 years versus Ն65 years), ethnicity (African American versus non-African American), sex, and a diagnosis of diabetes failed to identify significant treatment by subgroup interactions; however the power of the test was low given the many subgroups, some with small sample sizes.
Safety
The safety/tolerability findings of the combination treatments closely paralleled the well-known findings of the individual agents. The most frequently reported AE overall were headache (21%) and peripheral edema (20%). The frequency of headache was evenly distributed across all treatment groups (range, 13% to 28% for active treatment groups and 24% for placebo). Conversely peripheral edema occurred in 22% to 43% of patients receiving Ն10 mg of ER felodipine as monotherapy or combination therapy, com- ANCOVA ϭ analysis of covariance; ER ϭ extended-release. * Adjusted by analysis of covariance.
pared with 7% to 13% of patients receiving ER felodipine 2.5 mg as monotherapy or combination therapy and 11% of patients on placebo.
Fatigue and dizziness were reported in 7% and 6% of patients overall, respectively. Fatigue in patients receiving high-dose (400 mg) ER metoprolol succinate in combination with medium-to high-dose (10 and 20 mg) ER felodipine was relatively common (20% for 10/400 mg and 18% for 20/400 mg, and 2% to 9% for the other treatment groups). Dizziness was evenly distributed across treatment groups, with no discernible treatment-specific pattern (range 2% to 10%).
A total of 119 patients (11% overall) discontinued because of an AE. Within individual treatment groups, the largest AE discontinuation rates occurred with medium-to high-dose ER felodipine monotherapy (19% for 10 mg; 21% for 20 mg) and in combination with ER metoprolol succinate (range 6% to 18% for 10 mg, and 16% to 26% for 20 mg). The most common AE leading to discontinuation across all treatments included peripheral edema (4%), headache (2%), and fatigue (1%). The overall discontinuation rate in the placebo group was 11%.
No deaths occurred during the study, and patients with nonfatal serious AE that were possibly or probably attributed to the study drug included: subarachnoid hemorrhage (n ϭ 1; placebo), chest pain/atrial flutter (n ϭ 1; ER metoprolol succinate 25 mg), peptic ulcer (n ϭ 1; ER metoprolol succinate 25 mg), and chest pain (n ϭ 1; ER felodipine 20 mg/ER metoprolol succinate 100 mg).
Discussion
The M-FACT findings confirm that metoprolol succinate ER and felodipine ER both lower BP in a dose-dependent fashion in a hypertensive US population. Importantly M-FACT demonstrates that, by combining these two agents, the BP lowering attainable is almost fully additive over a wide range of doses. Additive effects might be expected as ␤-blockade reduces cardiac output and suppresses renin but increases peripheral vascular resistance while highly selective calcium channel blockers reduce peripheral resistance and can do so without notable changes in cardiac conduction.
The decreases in BP appreciated with the felodipine/ metoprolol combination also are substantial, ranging from 11.0 to 16.5 mm Hg reduction in SiDBP. Given that the majority of hypertensive patients have stage I or II disease (SBP 120 to Յ160 mm Hg; DBP 80 to Յ100 mm Hg), an ER felodipine/ER metoprolol succinate combination would be expected, on average, to lower BP to Ͻ140/90 mm Hg for much of the hypertensive population.
One can conclude from M-FACT that both ER felodipine and ER metoprolol succinate contribute to the effect of the combination. This finding would be expected to satisfy the regulatory basis for an approvable combination tablet. 20 -22 Furthermore the findings in M-FACT are consistent A positive difference implies less than and a negative sign implies greater than full additivity. ANCOVA ϭ analysis of covariance; ER ϭ extended-release. with other studies that have evaluated felodipine/metoprolol succinate combinations. 10 -17 In all, approximately 16 trials have evaluated felodipine doses of 1.25 to 20 mg and metoprolol succinate doses of 25 to 100 mg. Of particular note, Dalhöf et al showed in a three-way, crossover study of ER felodipine 5 mg/ER metoprolol succinate 50 mg with the option to increase to ER felodipine 10 mg/ER metoprolol succinate 100 mg that not only was the combination more effective than its individual components but that many patients could only reach goal BP with the combination. 15 The additivity of these particular dose levels was further confirmed in two additional studies. 16, 17 In addition, both felodipine and metoprolol are effective when used in combination with other agents such as diuretics. Thus, expanded combinations could provide treating physicians with an even wider range of effective treatments.
Data from M-FACT also indicate that ER metoprolol succinate 25 mg daily significantly reduces SiSBP/SiDBP from baseline to week 9 by a mean of 6.0/3.7 mm Hg over placebo and that this low dose of ER metoprolol succinate when combined with low doses of ER felodipine lowers BP to nearly the same degree as the very highest doses of the individual component agents.
Overall, 17% of randomized patients prematurely discontinued study participation, most (11% overall) for an AE and most in the high-dose felodipine group. There were no other distinguishing features among patients who prematurely discontinued the study (data not shown), and the time to discontinuation was not notably different across treatment groups.
Strengths of the current study include the factorial design, which examined a wide range of doses. As compared with traditional stepwise or dose-to-effect designs, these novel design features allow a clear determination of the additivity of the agents without confounding. This study went further than many other reports in quantifying and statistically testing the additivity. Quite remarkably, the study illustrated a nearly full additivity except perhaps at the extreme upper dose levels. Thus the data from this trial provides the treating physician with a very clear expectation for the magnitude of BP reductions with combinations of the agents.
Some limitations of the study should be acknowledged. A low proportion of African Americans (13%) and diabetic patients (11%) were enrolled, and may limit interpretations of results in these populations. The overall discontinuation rate for AE was low; however a higher AE-related discontinuation rate (particularly for headache, fatigue, edema, and flushing) was evident with high-dose ER felodipine. Like many antihypertensive drug trials, the study used a placebo run-in period. Although this differs from common practice, it allows washout of antecedent medications and provides a standard baseline upon which to judge antihypertensive effects. Importantly the M-FACT trial design did not mandate placebo run-in compliance criteria.
Clinical trials, including the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) 2 trial, show that long-term BP control usually requires a multidrug approach, which is supported by the guidelines for the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). 1 The M-FACT study illustrates that a combination felodipine/metoprolol ER product is a particularly useful approach to meeting these public health goals. It is also relevant to note that both these agents have been included in treatment regimens in large clinical trials that have validated the clinical outcome value of lowering BP with pharmacologic therapy. [7] [8] [9] The M-FACT study confirms that both ER felodipine and ER metoprolol succinate are effective antihypertensive agents that lower BP in a dose-dependent fashion and that the combination reflects their additive contribution. Because many patients discontinue antihypertensive treatment it is also an important finding from M-FACT that low-dose combinations of ER felodipine/ER metoprolol succinate can be as effective as very high doses of the individual agents while being associated with a low incidence of typical dose-related AE.
